AR108411A2 - HEPATITIS C VIRUS INHIBITORS - Google Patents
HEPATITIS C VIRUS INHIBITORSInfo
- Publication number
- AR108411A2 AR108411A2 ARP170101215A ARP170101215A AR108411A2 AR 108411 A2 AR108411 A2 AR 108411A2 AR P170101215 A ARP170101215 A AR P170101215A AR P170101215 A ARP170101215 A AR P170101215A AR 108411 A2 AR108411 A2 AR 108411A2
- Authority
- AR
- Argentina
- Prior art keywords
- imidazol
- pyrrolidinyl
- biphenylyl
- methyl
- methyl carbamate
- Prior art date
Links
Abstract
Reivindicación 1: Un compuesto, caracterizado porque se selecciona de: ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; (1R,1’R)-2,2’-(4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil))bis(N,N-dimetil-2-oxo-1-feniletanamina); ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; ((1S)-1-(((2S)-2-(4-(4’-(2-((2S)-4,4-difluoro-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-4-il)-4-bifenilil)-1H-imidazol-2-il)-4,4-difluoro-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; ((1S)-1-(((1R,3R,5R)-3-(5-(4’-(2-((1R,3R,5R)-2-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-azabiciclo[3.1.0]hex-3-il)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-2-azabiciclo[3.1.0]hex-2-il)carbonil)-2-metilpropil)carbamato de metilo; ((1R)-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etil)carbamato de metilo; ((1S)-2-metil-1-(((2S)-2-(5-(4’-(2-((2S)-1-(N-2-pirimidinil-D-valil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)propil)carbamato de metilo; ((1R)-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-2-(dimetilamino)-2-fenilacetil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-2-oxo-1-feniletil)carbamato de metilo; (4,4’-bifenildiilbis(1H-imidazol-5,2-diil(2S)-2,1-pirrolidindiil((1R)-2-oxo-1-fenil-2,1-etandiil)))biscarbamato de dimetilo; (1R)-N,N-dimetil-2-oxo-1-fenil-2-((2S)-2-(5-(4’-(2-((2S)-1-((2R)-tetrahidro-2-furanilcarbonil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)etanamina; ((1S)-2-((2S)-2-(5-(4’-(2-((2S)-1-(N-(metoxicarbonil)-L-alanil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)-1-metil-2-oxoetil)carbamato de metilo; y ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3,3-dimetilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2,2-dimetilpropil)carbamato de metilo.Claim 1: A compound, characterized in that it is selected from: ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; (1R, 1'R) -2,2 '- (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl)) bis (N, N-dimethyl-2 -oxo-1-phenylethanamine); ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (diethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) methyl carbamate; ((1S) -1 - (((2S) -2- (4- (4 '- (2 - ((2S) -4,4-difluoro-1 - ((2S) -2 - ((methoxycarbonyl) amino ) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-4-yl) -4-biphenylyl) -1H-imidazol-2-yl) -4,4-difluoro-1-pyrrolidinyl) carbonyl) -2- methylpropyl) methyl carbamate; ((1S) -1 - (((1R, 3R, 5R) -3- (5- (4 '- (2 - ((1R, 3R, 5R) -2 - ((2S) -2 - ((methoxycarbonyl ) amino) -3-methylbutanoyl) -2-azabicyclo [3.1.0] hex-3-yl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -2-azabicyclo [3.1.0] hex-2-yl) carbonyl) -2-methylpropyl) methyl carbamate; ((1R) -2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro-2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethyl) methyl carbamate; ((1S) -2-methyl-1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1- (N-2-pyrimidinyl-D-valil) -2- pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) propyl) methyl carbamate; ((1R) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -2- (dimethylamino) -2-phenylacetyl) -2-pyrrolidinyl ) Methyl -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -2-oxo-1-phenylethyl) methyl carbamate; (4,4'-biphenyldiylbis (1H-imidazol-5,2-diyl (2S) -2,1-pyrrolidindiyl ((1R) -2-oxo-1-phenyl-2,1-ethanediyl))) dimethyl biscarbamate ; (1R) -N, N-dimethyl-2-oxo-1-phenyl-2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2R) -tetrahydro -2-furanylcarbonyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) ethanamine; ((1S) -2 - ((2S) -2- (5- (4 '- (2 - ((2S) -1- (N- (methoxycarbonyl) -L-alanyl) -2-pyrrolidinyl) -1H- methyl imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) -1-methyl-2-oxoethyl) carbamate; and ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) -3.3 -dimethylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2,2-dimethylpropyl) methyl carbamate.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83699606P | 2006-08-11 | 2006-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108411A2 true AR108411A2 (en) | 2018-08-15 |
Family
ID=41175598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101215A AR108411A2 (en) | 2006-08-11 | 2017-05-09 | HEPATITIS C VIRUS INHIBITORS |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101558059B (en) |
AR (1) | AR108411A2 (en) |
TW (1) | TWI400072B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110281910A1 (en) * | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
TW201200522A (en) * | 2010-03-24 | 2012-01-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
US8921372B2 (en) * | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
MX366318B (en) * | 2010-11-19 | 2019-07-05 | Ligand Pharm Inc | Heterocycle amines and uses thereof. |
US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) * | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013067267A1 (en) * | 2011-11-03 | 2013-05-10 | Theravance, Inc. | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
CN103304551B (en) * | 2012-03-14 | 2017-06-13 | 北京凯因科技股份有限公司 | Hepatitis AG14361 |
US20160158200A1 (en) * | 2013-07-09 | 2016-06-09 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
CN106279121B (en) * | 2014-01-21 | 2019-05-24 | 杭州普晒医药科技有限公司 | The salt and crystal form or amorphous article, preparation method, pharmaceutical composition and purposes containing them of a kind of compound |
CN108084172A (en) * | 2014-02-21 | 2018-05-29 | 常州寅盛药业有限公司 | Anti- hepatitis C virus compound |
WO2015184644A1 (en) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof |
CN105524049B (en) * | 2014-09-28 | 2018-11-06 | 正大天晴药业集团股份有限公司 | Deuterated hepatitis C virus NS 5 A protein on NS inhibitor |
CN104546780A (en) * | 2014-12-12 | 2015-04-29 | 安徽一灵药业有限公司 | Daclatasvir film coating tablet preparation and preparation method thereof |
WO2017076358A1 (en) * | 2015-11-06 | 2017-05-11 | 苏州晶云药物科技有限公司 | New crystal form of imidazolyl biphenyl compound salt and preparation method thereof |
CN106496199A (en) * | 2016-10-19 | 2017-03-15 | 上海博志研新药物技术有限公司 | His Wei of Dacca and its preparation method of intermediate |
CN110382487B (en) * | 2017-03-22 | 2021-04-02 | 正大天晴药业集团股份有限公司 | Silicon-containing compounds for use against hepatitis c virus infection |
CN115448892B (en) * | 2022-09-19 | 2023-07-07 | 郑州铁路职业技术学院 | Synthesis method of benzothiadiazole heterocyclic compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003249977A1 (en) * | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
-
2007
- 2007-08-09 CN CN200780037723.7A patent/CN101558059B/en not_active Expired - Fee Related
-
2008
- 2008-02-13 TW TW097105080A patent/TWI400072B/en not_active IP Right Cessation
-
2017
- 2017-05-09 AR ARP170101215A patent/AR108411A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200934486A (en) | 2009-08-16 |
CN101558059A (en) | 2009-10-14 |
TWI400072B (en) | 2013-07-01 |
CN101558059B (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108411A2 (en) | HEPATITIS C VIRUS INHIBITORS | |
EA201000300A1 (en) | METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C | |
HK1144089A1 (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2- ((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5- yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2- methylpropyl)carbamate dihydrochloride salt | |
NZ594981A (en) | Hepatitis c virus inhibitors | |
HRP20120440T1 (en) | Hepatitis c virus inhibitors | |
PE20160800A1 (en) | METHYL ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL COMBINATION )-1H-IMIDAZOL-5-IL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-IL-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE (DACLATASVIR) AND N-(TERT-BUTOXICARBONYL)-3- METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXYN-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOIL)-2-VINYLCYCLOPROPYL) -L-PROLINAMIDE (ASUNAPREVIR). | |
HRP20120706T1 (en) | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors | |
NZ595168A (en) | Hepatitis c virus inhibitors | |
NZ605440A (en) | Solid compositions comprising an hcv inhibitor | |
NZ594068A (en) | Substituted benzimidazole compounds as hepatitis c virus inhibitors | |
JP2013510857A5 (en) | ||
PE20121354A1 (en) | HEPATITIS C VIRUS INHIBITORS | |
HRP20160410T1 (en) | Hepatitis c virus inhibitors | |
JP2011530531A5 (en) | ||
PE20140038A1 (en) | ANTIVIRAL COMPOUNDS | |
JP2012518000A5 (en) | ||
JP2012522056A5 (en) | ||
JP2010500415A5 (en) | ||
JP2010500414A5 (en) | ||
EA200400183A1 (en) | CRYSTALS CONTAINING SALT N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-Fluoro-2-OXO-1,2-DIHYDRO-3H-INDOL-3-ILIDEN) METHYL] -2,4-DIMETHYL- 1H-PIRROL-3-CARBOXAMIDE WITH APPLE ACID, METHODS FOR THEIR PRODUCTION AND THEIR COMPOSITION | |
PE20120533A1 (en) | HEPATITIS C VIRUS INHIBITORS | |
RU2008112683A (en) | FAP INHIBITORS | |
JP2012522053A5 (en) | ||
PE20061373A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE | |
KR910006224A (en) | Amino acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |